Related Experiment Video
Updated: Jul 9, 2026

Estimation of Urinary Nanocrystals in Humans using Calcium Fluorophore Labeling and Nanoparticle Tracking Analysis
Published on: February 9, 2021
Urinary markers in screening patients with hematuria
Edmund Chiong1, Kris E Gaston, H Barton Grossman
1Department of Urology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1373, Houston, TX 77030, USA.
Abstract:
Hematuria is a common presenting symptom of urothelial malignancy. Although conventional urine analysis is very sensitive in detecting the presence of hematuria, it is not specific in detecting bladder cancer or other urinary-tract cancers. The noninvasive urinary tests NMP22 and UroVysion have been approved by the U.S. Food and Drug Administration for bladder cancer screening. These tests have better sensitivity than cytology for detecting bladder cancer in patients who present with hematuria. The positive predictive values of both tests increase in individuals with hematuria who have risk factors for bladder cancer. Evaluating hematuria with sensitive markers, such as NMP22 and UroVysion, in high-risk populations offers an opportunity to develop effective strategies for bladder cancer screening.
Related Concept Videos
Urine Studies I: Urinalysis
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Urinary Tract Calculi III: Medical Management
Imaging Studies II: Ultrasonography
Serum Studies: Renal Function Tests
Nursing Assessment of the Genitourinary System I: Health History